Investors should monitor the outcome of the contested board election, as a shift in board composition could lead to changes in capital allocation and strategy. The upcoming 2026 clinical data readouts are critical catalysts that could validate the company's pipeline progress and influence stock performance.
Price Chart
Executive Summary
Pacira BioSciences is advancing its 5x30 strategy with strong commercial momentum, highlighted by 6.2% year-over-year volume growth for EXPAREL and record-high gross margins. The company is entering a data-rich period with key 2026 catalysts from its pipeline. However, the annual meeting is contested, with activist investor DOMA Perpetual nominating three director candidates, challenging the board's composition and capital allocation strategy.
Key Facts
- EXPAREL achieved 6.2% year-over-year volume growth in 2025, with 8% growth in the second half.
- The company delivered record-high 2025 GAAP and Non-GAAP Gross Margins of 79% and 81%, respectively.
- Pacira returned $150 million to stockholders through share repurchases in 2025.
- The company is entering a data-rich period with key 2026 readouts expected for PCRX-201, ZILRETTA in shoulder OA, and iovera in spasticity.
- Activist investor DOMA Perpetual has nominated three director candidates, leading to a contested election at the annual meeting.
Financial Impact
The company repurchased $150 million in shares in 2025 and has a new $300 million authorization. The 5x30 strategy aims for double-digit compounded annual growth and a five-percentage point gross margin improvement by 2030.
Risk Factors
- The contested board election creates uncertainty around future strategic direction.
- The company faces potential generic competition for EXPAREL starting in 2030, despite a volume-limited settlement.
- The stock price performance in 2025 was negatively impacted by patent litigation, which could affect investor sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREC14A Filing (Primary) | 0001104659-26-044908 |
| Document: 0001104659-26-044908-index-headers.html | 0001104659-26-044908 |
| Document: 0001104659-26-044908-index.html | 0001104659-26-044908 |
| Document: 0001104659-26-044908.txt | 0001104659-26-044908 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.21 (−1.45%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.21 (−1.48%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.21 (−0.63%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.21 (+10.86%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.21 (+10.81%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.21 (+11.20%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.21 (+13.30%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.21 (+6.46%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.21 (+4.87%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.21 (+7.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access